Pharmacogenetics in major depression: A comprehensive meta-analysis

详细信息    查看全文

• 作者：Tomihisa Niitsu ; Chiara Fabbri ; Francesco Bentini ; Aless ; ro Serretti
• 关键词：MD ; major depression ; MDD ; major depressive disorder ; AD(s) ; antidepressant(s) ; GWAS ; genome-wide association study ; LD ; linkage disequilibrium ; STAR*D ; Sequenced Treatment Alternatives to Relieve Depression ; GENDEP ; Genome-based Therapeutic Drugs for Dep
• 刊名：Progress in Neuro-Psychopharmacology and Biological Psychiatry
• 出版年：2013
• 出版时间：1 August, 2013
• 年：2013
• 卷：45
• 期：Complete
• 页码：183-194
• 全文大小：944 K

文摘

A number of candidate gene studies focused on major depression (MD) and antidepressant (AD) efficacy have been carried out, but results mainly remain inconclusive. We performed a comprehensive meta-analysis of published candidate gene studies focused on AD efficacy in MD to evaluate the cumulative evidence. A random-effect model was applied to study the polymorphisms with genotypic counts available from at least three independent studies. On the base of previous evidence, the analysis was stratified by ethnicity (Caucasian, Asian, and other/mixed), and AD class (SSRIs and mixed/other ADs).

Genotypic data were available for 16 polymorphisms in 11 genes. After the exclusion of 5-HTTLPR in SLC6A4 included in another recent meta-analysis, 15 polymorphisms in 11 genes were included in the present meta-analysis (BDNF rs6265, SLC6A4 STin2, HTR1A rs6295, HTR2A rs6311, rs6313 and rs7997012, HTR6 rs1805054, TPH1 rs1800532, SLC6A2 rs5569, COMT rs4680, GNB3 rs5443, FKBP5 rs1360780 and rs3800373, and ABCB1 rs1045642 and rs2032582).

Our results suggested that BDNF rs6265 (Val66Met) heterozygous genotype was associated with better SSRIs response compared to the homozygous genotypes, particularly in Asians (OR = 1.53, 95 % CI 1.12-2.07, p = 0.007). SLC6A4 STin2, HTR2A rs6311 and rs7997012, GNB3 rs5443, FKBP5 rs1360780 and rs3800373, and ABCB1 rs2032582 showed associations with AD efficacy, but these results were highly dependent on one or two single studies.

In conclusion, our findings suggested the BDNF Val66Met as the best single candidate involved in AD response, with a selective effect on SSRI treatment. Our overall results supported no major effect of any single gene variant on AD efficacy.